Skip to main content
SpringerLink
Log in

Probrain Natriuretic Peptide for assessment of efficacy in heart failure treatment

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

N-terminal probrain natriuretic peptide (NT-proBNP) is elevated in patients with heart failure. Numerous clinical trials have evaluated the efficacy of spironolactone in heart failure; however, no studies have directly examined the effects of spironolactone treatment on NT-proBNP level. This study investigated whether NT-proBNP levels decrease with daily spironolactone treatment. The study consisted of 117 adult patients with heart failure. All participants were divided into 3 groups, class I, class II, and class III, according to the New York Heart Association classification system. Patients were randomly assigned to receive spironolactone or were treated with another drug, other than spironolactone, as placebo. NT-proBNP plasma samples were taken at baseline and after 6 mo of treatment. A total of 62 patients were treated with daily spironolactone; 55 patients were followed with available treatment without spironolactone. The baseline demographic and laboratory parameters were similar for patients in all groups. At the end of 6 mo, spironolactonetreated patients had significantly lower NT-proBNP levels and significantly better ejection fractions than did patients in all New York Heart Association classes who were not treated with spironolactone. Results suggest that spironolactone decreases plasma NT-proBNP concentrations, and that the measurement of plasma NT-proBNP levels may be helpful in assessing therapeutic efficacy in patients who are treated for heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.Circulation. 1981;63:645–651.

    PubMed  CAS  Google Scholar 

  2. Rouleau JL, Packer M, Moye L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.J Am Coll Cardiol. 1994;24:583–591.

    Article  PubMed  CAS  Google Scholar 

  3. Weber KT. Aldosterone and spironolactone in heart failure.N Engl J Med. 1999;341:753–755.

    Article  PubMed  CAS  Google Scholar 

  4. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N Engl J Med. 1999;341:709–717.

    Article  PubMed  CAS  Google Scholar 

  5. Levin ER, Gardner DG, Samson WK. Natriuretic peptides.N Engl J Med. 1998;339:321–328.

    Article  PubMed  CAS  Google Scholar 

  6. Bay M, Kirk V, Parner J, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function.Heart. 2003;89:150–154.

    Article  PubMed  CAS  Google Scholar 

  7. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians.Rev Cardiovasc Med. 2003;4:72–80.

    PubMed  Google Scholar 

  8. Remes J, Tikkanen I, Fyhrquist F, Pyorala K. Neuroendocrine activity in untreated heart failure.Br Heart J. 1991;65:249–255.

    Article  PubMed  CAS  Google Scholar 

  9. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.Circulation. 1990;82:1730–1736.

    PubMed  CAS  Google Scholar 

  10. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure.Curr Cardiol Rep. 2000;2:198–205.

    Article  PubMed  CAS  Google Scholar 

  11. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction.Lancet. 1998;351:9–13.

    Article  PubMed  CAS  Google Scholar 

  12. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment.Clin Endocrinol (Oxf). 1997;47:287–296.

    Article  CAS  Google Scholar 

  13. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.J Am Coll Cardiol. 2006;47:345–353.

    Article  PubMed  CAS  Google Scholar 

  14. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.Circulation. 1997;96:509–516.

    PubMed  CAS  Google Scholar 

  15. Stanek B, Frey B, Hulsmann M, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.J Am Coll Cardiol. 2001;38:436–442.

    Article  PubMed  CAS  Google Scholar 

  16. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.J Am Coll Cardiol. 2001;37:386–391.

    Article  PubMed  CAS  Google Scholar 

  17. Richards M, Nicholls MG, Espiner EA, et al, Christchurch Cardioendocrine Research Group, Australia-New Zealand Heart Failure Group. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.J Am Coll Cardiol. 2006;47:52–60.

    Article  PubMed  CAS  Google Scholar 

  18. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.Am J Med. 2001;110:438–441.

    Article  PubMed  CAS  Google Scholar 

  19. Georges B, Beguin C, Jadoul M. Spironolactone and congestive heart failure.Lancet. 2000; 355:1369–1370.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family Medicine, Fatih University, School of Medicine, Ankara, Turkey

    Adem Ozkara & Oguz Tekin

  2. Department of Nephrology, Fatih University, School of Medicine, Ankara, Turkey

    Faruk Turgut, Mehmet Kanbay & Ali Akcay

  3. Department of Cardiology, Fatih University, School of Medicine, Ankara, Turkey

    Yusuf Selcoki & Aydin Karanfil

  4. Department of Radiology, Fatih University, School of Medicine, Ankara, Turkey

    Melike Rusen Metin

Authors
  1. Adem Ozkara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faruk Turgut
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuf Selcoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aydin Karanfil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Melike Rusen Metin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mehmet Kanbay
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Oguz Tekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ali Akcay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faruk Turgut.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozkara, A., Turgut, F., Selcoki, Y. et al. Probrain Natriuretic Peptide for assessment of efficacy in heart failure treatment. Adv Therapy 24, 1233–1239 (2007). https://doi.org/10.1007/BF02877769

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02877769

Keywords

Search

Navigation